EC approves Cabotegravir LA by ViiV Healthcare for HIV prevention
ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced that the European Commission (EC) has authorized Apretude, also known as cabotegravir ... Read More
Strides Pharma’s HIV generic drug gets tentative FDA approval
Strides Pharma Science Limited (Strides) announced that its Singapore-based stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, has received tentative approval for Dolutegravir 50mg ... Read More
Aurobindo Pharma gets tentative FDA approval for generic HIV treatment for children
Aurobindo Pharma Limited has achieved a significant milestone by securing the US Food and Drug Administration (FDA)'s tentative nod under the PEPFAR program for its ... Read More
Lupin gains tentative FDA approval for Dolutegravir Tablets generic
Indian pharmaceutical company Lupin announced that the US Food and Drug Administration (FDA) has granted tentative approval for its Abbreviated New Drug Application (ANDA) for ... Read More
ViiV Healthcare’s Cabenuva secures FDA approval for HIV treatment
ViiV Healthcare has received FDA approval for Cabenuva, a long-acting treatment regimen for HIV-1 infection in adult patients. This new therapy is poised to transform ... Read More
ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options
Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a ... Read More
ViiV Healthcare secures Dovato EMA approval for HIV-1 treatment
Dovato EMA approval : The European Commission (EC) has approved ViiV Healthcare’s once-daily, single-pill, two-drug regimen Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus ... Read More
FDA approves ViiV Healthcare’s Juluca for maintenance treatment of HIV-1
ViiV Healthcare, a joint venture between GlaxoSmithKline (GSK), Pfizer, and Shionogi, has received approval from the U.S. Food and Drug Administration (FDA) for its two-drug ... Read More